
A UCLA Health and Mount Sinai project will study persistent UC symptoms. Understand its questions, planned methods and implications for food choices.

On 2026-10-05, UCLA Health announced that its gastroenterologist Lin Chang and Mount Sinai’s Bruce Sands had received a $4 million grant from the National Institutes of Health to investigate persistent digestive symptoms in ulcerative colitis (UC). The planned research will examine why IBS-like bloating, irregular bowel movements and cramping can continue when inflammation appears minimal or absent.
The announcement builds on an existing clinical distinction: ulcerative colitis and irritable bowel syndrome (IBS) are separate conditions. It describes IBS as a condition that does not cause inflammation. Yet the symptoms identified in this UC project resemble those associated with IBS.
That overlap explains the wording “IBS-like.” The researchers are focusing on bloating, irregular bowel movements and cramping in people who have UC. The phrase describes a symptom pattern within the population being studied.
UCLA Health’s announcement reports that these symptoms persist in about one in three people with UC when inflammation is minimal or absent. The figure gives the project its practical importance: symptoms remain an important question even when visible inflammation has subsided.
Two different observations therefore sit behind the study. One concerns how much inflammation appears to be present. The other concerns what a person continues to feel or experience in their bowel patterns.
The useful starting point is to keep both observations in view rather than let one replace the other. Keeping those descriptions distinct is useful when putting digestive symptoms into words or reading about different forms of gut inflammation.
According to the UCLA Health announcement, Chang and Sands will lead a five-year collaboration between UCLA and Mount Sinai that is scheduled to conclude in June 2031. The investigators plan to assess ongoing gut inflammation and altered gut-brain signaling as possible explanations for persistent symptoms.
The shift is in the question being asked. Rather than treating a quieter inflammatory picture as the end of the inquiry, the project places continuing digestive symptoms at the center of its design. It asks how biological and nervous-system measures might help explain those symptoms.
An inflammation-focused part of the project will examine whether ongoing gut inflammation is connected with the symptoms being studied. This keeps the gut itself within the investigation even though the project focuses on people with little or no apparent active inflammation.
For readers, that detail matters because the headline involves more than a search for a nervous-system explanation. The study is designed to consider inflammatory and signaling possibilities together. Its question includes either explanation or a contribution from both.
Gut-brain signaling refers to communication between the digestive system and the brain. The announcement places that communication alongside ongoing inflammation as a possible contributor. Both are being approached as questions about the biology behind continuing symptoms.
For someone reading the news, the key distinction is between a symptom description and an explanation. Bloating identifies what is happening. A proposed change in gut-brain signaling is a hypothesis about why it may be happening.
The announcement describes several methods:
These methods place symptom reports alongside measures of the brain and nervous system. The stimulation component asks an additional question: whether a particular intervention changes symptoms within the study.
The mix of methods matters because the original problem is not simply a brain image or a nervous-system reading. It is continuing bloating, cramping and changes in bowel patterns. A biological explanation becomes useful to this research question when it helps account for that experience.
The value of this framing is that it connects the body's measures with the symptoms the project is intended to help explain. Inflammation remains part of the inquiry. Nervous-system function is another part. The study puts those elements alongside the problem that people with UC continue to experience.
That also provides a useful lens for reading future reports from the project. A finding about a biological measure and a finding about symptom improvement would answer different questions. The first would concern a possible explanation. The second would concern whether the tested approach changed the experience that motivated the study.
The stated longer-term aim is to support more personalized treatment approaches for people with UC who have persistent IBS-like symptoms despite little or no active inflammation.
In practical terms, the research is asking whether different explanations might matter for different people within this UC group. That is a more specific goal than assuming that everyone with a similar symptom pattern shares the same underlying problem.
The plan is easier to follow when its questions are kept separate:
This sequence moves from understanding symptoms toward possible application. It gives readers a way to track the research without collapsing every part of the project into a single claim. The questions are connected, but each asks for a different kind of answer.
This is a funded research plan rather than a report of completed findings. Neither residual inflammation nor altered gut-brain signaling has been established by this announcement as the cause of these symptoms. The findings will need to come from the investigation itself.
The phrase “inflammation has subsided” also needs care. It does not mean that inflammation has been ruled out for every person with ongoing symptoms. The project includes ongoing inflammation among its possible explanations, so the quieter inflammatory picture should not be treated as proof that signaling is responsible.
The reported one-in-three estimate also needs context. The available announcement details do not identify the underlying study, the population or the measurement criteria behind it. It is best understood as UCLA Health’s reported estimate rather than a universal rate that applies to every UC setting.
The terminology has another boundary: IBS-like symptoms do not establish an IBS diagnosis. The similarity is the reason for the description, not a conclusion about what any individual has. The project concerns people with UC and continuing symptoms rather than everyone who experiences bloating or irregularity.
The planned methods should also stay in their research context. The announcement does not establish brain imaging or autonomic-function wearables as routine diagnostic tools for this situation. It does not show that non-invasive vagal nerve stimulation improves symptoms; that is a question the researchers plan to test.
Finally, the ambition to inform more personalized approaches is a goal rather than a demonstrated outcome. The scheduled conclusion in June 2031 is a project timeline, not a promise that new clinical options will be ready then.
For daily dietary choices, the sensible implication is not a new list of foods to avoid. This project puts the emphasis on understanding persistent symptoms rather than assigning them a dietary explanation.
Personal food decisions that form part of UC care belong in a discussion with a qualified healthcare professional. The useful shift here is toward better questions about ongoing discomfort, not more confident assumptions about its cause.
The editorial takeaway is straightforward: take persistent symptoms seriously while keeping any food response individual. A more restrictive plate is not the message of this grant.
Persistent UC symptoms can be misread when a quieter inflammation picture is treated as a complete explanation of digestive wellbeing. DigestGenius’s free articles and in-depth resources put bloating and bowel-pattern questions into context through readable explanations of digestive research, helping adults judge conflicting advice without turning a proposed mechanism into a universal answer.
DigestGenius publishes research-led guidance on digestion, the gut microbiome, fiber, probiotics, gut-brain signaling, inflammation and everyday digestive wellbeing.



Explore clear, research-led guidance on digestion, the microbiome, food, fiber, probiotics and the gut-brain connection.
read the blog